Recently, Novo Nordisk's Smegglutide tablets (trade name: Novo Nordisk) have been approved for marketing by the National Medical Products Administration (NMPA) for the treatment of type 2 diabetes. It is reported that this is the first domestically approved oral GLP-1 (glucagon like peptide-1) receptor agonist. Semaglutide is a glucagon like peptide-1 (GLP-1) analogue. GLP-1 is a peptide hormone secreted by intestinal cells. It stimulates insulin secretion by binding to GLP-1 receptors and inhibits glucagon secretion, thereby promoting glucose metabolism. At the same time, it can also have the effect of delaying gastric emptying and suppressing appetite. Natural GLP-1 is secreted by people after meals, stimulated by glucose. In June 2021, the weight loss indication of Smegglutide was approved for marketing by the US Food and Drug Administration (FDA), and it was also the first weekly GLP-1 receptor agonist used for weight management. Clinical studies have shown that after 12 weeks of subcutaneous injection of smeglutide once a week, the average weight loss of obese or overweight patients in the 2.4mg dose group was about 6%; At 68 weeks, the weight loss range is 17% -18%. Therefore, Smegglutide is also known as the "miracle drug for weight loss". With the approval of Smegglutide tablets, China's GLP-1RA class drugs have officially entered the era of oral administration, undoubtedly further promoting the growth of the drug market. Many domestic enterprises have targeted the market potential of GLP-1 drugs, especially in the field of weight loss, and have made deep layout. At present, more than 20 companies have entered the clinical development stage of GLP-1 drugs for weight loss indications, and there are more drugs in the preclinical research stage. Among them, Liraglutide generic drugs from East China Pharmaceutical and Benarutide from Renhui Biotechnology have successfully obtained market approval for weight loss indications. At the same time, Lilly's Telposide and Novo Nordisk's Smegglutide are also in the new drug application stage. In addition, innovative drugs such as IBI362 from Xinda Biotechnology, XW003 injection from Xianda Biotechnology, Orforflipron capsules from Eli Lilly, and CagriSema from Novo Nordisk have entered the final stage of clinical trials, which is phase 3 clinical trials. (Lai Xin She)